Biocad
As of the edition of 20 October 2026, Biocad runs 27 drugs; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 12 |
| Went quiet | 7 |
| Stopped | 2 |
| Status not established | 6 |
| Total | 27 |
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Biocad needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 18 trials led
- Cancer: 17 trials led
- Immune system: 10 trials led